Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- GYRE
- Price
- 8.05
- Stock movement down
- -0.25 (-3.01%)
- Company name
- Gyre Therapeutics Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 775.48M
- Ent value
- 757.05M
- Price/Sales
- 7.23
- Price/Book
- 5.64
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 116.60
- Forward P/E
- 43.92
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -26.55%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GYRE does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 116.60 |
| Price to OCF | 200.02 |
| Price to FCF | 574.86 |
| Price to EBITDA | 51.59 |
| EV to EBITDA | 50.36 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.23 |
| Price to Book | 5.64 |
| EV to Sales | 7.06 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 96.33M |
| EPS (TTM) | 0.06 |
| FCF per share (TTM) | 0.01 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 107.27M |
| Gross profit (TTM) | 102.42M |
| Operating income (TTM) | 11.97M |
| Net income (TTM) | 6.65M |
| EPS (TTM) | 0.06 |
| EPS (1y forward) | 0.18 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 95.48% |
| Operating margin (TTM) | 11.16% |
| Profit margin (TTM) | 6.20% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 40.40M |
| Net receivables | 25.88M |
| Total current assets | 98.58M |
| Goodwill | 0.00 |
| Intangible assets | 4.85M |
| Property, plant and equipment | 30.54M |
| Total assets | 159.38M |
| Accounts payable | 556.00K |
| Short/Current long term debt | 1.17M |
| Total current liabilities | 15.91M |
| Total liabilities | 21.97M |
| Shareholder's equity | 137.41M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 3.88M |
| Capital expenditures (TTM) | 2.53M |
| Free cash flow (TTM) | 1.35M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 4.84% |
| Return on Assets | 4.17% |
| Return on Invested Capital | 4.82% |
| Cash Return on Invested Capital | 0.98% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.23 |
| Daily high | 8.38 |
| Daily low | 8.00 |
| Daily Volume | 67K |
| All-time high | 47155.50 |
| 1y analyst estimate | 18.00 |
| Beta | 7.07 |
| EPS (TTM) | 0.06 |
| Dividend per share | 0.00 |
| Ex-div date | 13 Jan 2023 |
| Next earnings date | 31 Mar 2026 |
Downside potential
Loading...
Downside potential data
| GYRE | S&P500 | |
| Current price drop from All-time high | -99.98% | -0.89% |
| Highest price drop | -99.99% | -19.00% |
| Date of highest drop | 1 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -99.98% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
775.48M
Marketcap category
Small-cap
Description
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Employees
579
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partner